Dilemmas in the curative treatment of lung cancer in elderly patients;Dylematy radykalnego leczenia onkologicznego chorych na raka płuca w okresie starości

Pneumonologia i Alergologia Polska

Volumn 77, Issue 2, 2009, Pages 166-172

  Kȩpka, Lucyna ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Chemotherapy; Elderly; Lung cancer; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; CLINICAL TRIAL; HUMAN; INCIDENCE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; POLAND; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; INCIDENCE; LUNG NEOPLASMS; PALLIATIVE CARE; POLAND; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 69849084534     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Szczuka I., Roszkowski-Śliz K. Rak płuca w Polsce w latach 1970-2004. Pneumonol. Alergol. Pol. 2008; 76: 19-28.
2. Krajowy Rejestr Nowotworów. Raporty na podstawie danych Zakładu Epidemiologii i Prewencji Nowotworów Centrum Onkologii Instytutu w Warszawie. Publikacja elektroniczna.
3. Owonikoko T.K., Ragin C.C., Belani C.P. i wsp. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J. Clin. Oncol. 2007; 25: 5570-5577.
4. Jassem J., Drosik K., Dziadziuszko R. i wsp. Systemowe leczenie raka płuca i miȩdzybłoniaka opłucnej: uaktualnione zalecenia oparte na wynikach wiarygodnych badań klinicznych. Pneumonol. Alergol. Pol. 2008; 76: 44-52.
5. Asmis T.R., Ding K., Seymour L. i wsp. Age and comorbidity as independent prognostic factors in the treatment of non-small cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J. Clin. Oncol. 2008; 26: 54-59.
6. Jatoi A., Hillman S., Stela P. i wsp. Should elderly non-small-cell lung cancer patients be offered, elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J. Clin. Oncol. 2005; 23: 9113-9119.
7. Balducci L. Geriatric oncology: challenges for the new century. Eur. J. Cancer 2000; 36: 1741-1754.
8. Brock M.V., Kim M.P., Hooker C.M. i wsp. Pulmonary resection in octogenarians with stage I non-small cell lung cancer: a 22-year experience. Ann Thorac Surg 2004; 77: 271-277.
9. Port J.L., Kent M., Korst R.J. i wsp. Surgical resection for lung cancer in the octogenarian. Chest 2004; 126: 733-738.
10. Rostad H., Strand T.E., Naalsund A., Talleraas O., Norstein J. Lung cancer surgery: the first 60 days. A population-based study. Eur. J. Cardiothorac Surg. 2006; 29: 824-828.
11. Finlayson E., Fan Z., Birkmeyer J.D. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J. Am. Coll. Surg. 2007; 205: 729-734.
12. Tanoue LT, Gettinger S. Treatment of lung cancer in older patients. Clin. Chest Med. 2007; 28: 735-749.
13. Shaw J.P., Dembitzer F.R., Wisnivesky J.P. i wsp. Video-assisted thoracoscopic lobectomy: state of the art and future directions. Ann. Thorac Surg. 2008; 85: 705-709.
14. Pennathur A., Abbas G., Christie N., Landreneau R., Luketich J.D. Video assisted thoracoscopic surgery and lobectomy, sublobar resection, radiofrequency ablation, and stereoatactic radiosurgery: advances and controversies in the management of early stage non-small cell lung cancer. Curr. Opin. Pulm. Med. 2007; 13: 267-270.
15. Jeremic B., Classen J., Bamberg M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54: 119-130.
16. Nagata Y., Takayama K., Matsuo Y. i wsp. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int., J. Radiat, Oncol. Biol, Phys. 2005; 63: 1427-1431.
17. Zimmermann F.B., Geinitz H., Schill S. i wsp. Stereotactic hypofractionated radiation therapy for stage I non-small-cell lung cancer. Lung Cancer 2005; 48: 107-114.
18. Timmerman R., McGarry R.C., Yiannoutsos C i wsp. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol. 2006; 24: 4833-4838.
19. Vrdoljak E., Mise K., Sapumar D., Rozga A., Marusić M. Survival analysis of untreated patients with non-small-cell lung cancer. Chest. 1994; 106: 1797-1800.
20. McGarry RC, Song G, des Rosiers P, Timmerman R. Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest 2003; 121: 1155-1158.
21. Raz D.J., Zell J.A., Ou S.H., Gandara D.R., Anton-Culver H., Jablons D.M. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 2007; 132: 193-199.
22. Van Meerbeeck J.P., Kramer G.W.P.M., Van Schil P.E.Y. i wsp. Randomised controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. J. Natl. Cancer. Inst. 2007; 99: 442-450.
23. Albain K.S., Swann R.S., Rusch V.R. i wsp. Phase III study of concurrent, chemotherapy and radiotherapy (CT/RT) vs. CT/RT followed by surgical resection for stage III (pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). Proc. Am. Soc. Clin. Oncol. 2005; 23: 624.
24. Pignon T., Gregor A., Schaake Koning C., Roussel A., van Glabbeke M., Scalliet P. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother. Oncol. 1998; 46: 239-248.
25. Baumann M. Is curative radiation therapy in elderly patients limited by increased normal tissue toxicity? Radiother. Oncol. 1998; 46: 225-227.
26. Werner-Wasik M., Scott C., Cox J.D. i wsp. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48: 1475-1482.
27. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 1995; 311: 899-909.
28. Jassem J. The role of radiotherapy in lung cancer: Where is the evidence? Radiother. Oncol. 2007; 83: 203-213.
29. Rowell N.P., O'Rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. The Cochrane Database of Systematic Reviews 2004; 4:CD002140.pub2. DOI: 10.1002/14651858. CD002140.pub.2.
30. Movsas B., Scott C., Sause W. i wsp. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies. Int. J. Radiat. Oncol. Biol. Phys. 1999; 45: 1143-1149.
31. Schild S.E., Stella P.J., Geyer S.M. i wsp. The outcome of combined modality therapy for stage III non-small-cell lung cancer in the elderly.J. Clin. Oncol. 2003; 21: 3201-3206.
32. Sequist L.V., Lynch T.J. Aggressive treatment for the fit elderly with non-small cell lung cancer? Yes. J. Clin. Oncol. 2003; 21: 3186-3188.
33. Extermann M., Albrandt G., Chen H. i wsp. Are older French patients as willing as older American patients to undertake chemotherapy? J. Clin. Oncol. 2003; 21: 3214-3219.
34. Baumann M., Herrmann T., Koch R. i wsp. Continuous hyperfractionated accelerated radiotherapy -weekend less (CHARTWEL) versus conventionally fractionated (CF) in non-small-cell lung cancer (NSCLC): First results of a phase III randomised multicentre trial (ARO 97-1). Eur. J. Cancer 2005; 3: 323.
35. Kȩpka L. Zbadanie czȩstości i przyczyn niepowodzeń w klatce piersiowej po tröjwymiarowej konformalnej radioterapii u chorych na niedrobnokomórkowego raka płuca. (Rozprawa habilitacyjna). Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie. Warszawa 2006.
36. Pignon J.P., Arriagada R., Ihde D.C. i wsp. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 1992; 327: 1618-1624.
37. Auperin A., Arriagada R., Pignon J.P. i wsp. Prophylactic cranial irradiation for patents with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N. Engl. J. Med. 1999; 341: 478-484.
38. Quon H., Shepherd F.A., Payne D.G. i wsp. The influence of age on the delivery tolerance and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int. J. Radiat. Oncol. Biol, Phys. 1999; 43: 39-45.
39. Youen A.R., Zou G., Turrisi A.T. iwsp. Similar outcome of elderly patients in Intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000; 89: 1953-1960.
40. Schild S.E., Stella B.J., Brooks B.J. i wsp. Results of combined-modality therapy for limited-stage small cell, lung carcinoma in the elderly. Cancer 2005; 103: 2349-2354.
41. Jeremić B., Shibamoto Y., Acimović L., Milisavljevifi S. Carboplatin, etoposide and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma. Cancer 1998; 82: 838-841.
42. Murray N., Grafton C., Shah A. i wsp. Abbreviated treatment for elderly, infirm or noncompliant patients with limited stage small-cell lung cancer. J. Clin. Oncol. 1998; 16: 3323-3328.
43. De Ruyscher D., Pijls-Johannesma M., Bentzen S.M. i wsp. Time between the first day of chemotherapy and the last day of chest radiation is the most, important predictor of survival in limited disease small-cell lung cancer. J. Clin. Oncol. 2006; 24: 1057-1063.
44. Videtic G.M.M., Belderbos J.S.A., Kong F.-M., Kepka L., Martel M., Jeremić B. Perspectives on elective nodal irradiation in lung cancer: Report from the 2006 IAEA consultants' meeting. Part II: Small-Cell Lung Cancer (SCLC). Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 327-334.
45. Lee J.J., Bekele B.N., Zhou X., Cantor S.B., Komaki R., Lee J.S. Decision analysis for prophylactic cranial irradiation for patients with small cell lung cancer. J. Clin. Oncol. 2006; 24: 3597-3603.
46. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer. www.nccn.org. Publikacja elektroniczna.